Investors & Media
4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. 4DMT seeks to unlock the full potential of genetic medicines using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent targeted and evolved vectors for use in our products. Learn more about our pipeline HERE.
Latest Corporate Presentation
November 14, 2022 at 8:00 AM EST
November 03, 2022 at 4:30 PM EDT
September 30, 2022 at 9:00 AM EDT